Prolight Diagnostics publishes investor letter for August 2025
1 augusti, 11:00
1 augusti, 11:00
The investor letter notes, among other things, that all potential partners we met during the ADLM congress were highly impressed by Psyros’ performance, with its ability to deliver high sensitivity results combined with its sleek compact look, intelligent features and very competitively priced consumable cartridge.
The investor letter is available via the attached file or on the company’s website: https://prolightdx.com/en/mediaeng/investor-letters/
For further information, please contact:
Ulf Bladin, CEO
E-mail: info@prolightdx.com
Phone: +46 73 582 39 87
Company website: www.prolightdx.com
About Us
Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.
The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.
Attachments
Prolight Diagnostics - Investor letter August 1 2025
Prolight Diagnostics publishes investor letter for August 2025
1 augusti, 11:00
The investor letter notes, among other things, that all potential partners we met during the ADLM congress were highly impressed by Psyros’ performance, with its ability to deliver high sensitivity results combined with its sleek compact look, intelligent features and very competitively priced consumable cartridge.
The investor letter is available via the attached file or on the company’s website: https://prolightdx.com/en/mediaeng/investor-letters/
For further information, please contact:
Ulf Bladin, CEO
E-mail: info@prolightdx.com
Phone: +46 73 582 39 87
Company website: www.prolightdx.com
About Us
Prolight Diagnostics AB develops innovative Point-of-Care systems. These are small, portable instruments and disposable cartridges for performing in-vitro diagnostic (IVD) tests from a drop of blood. We want to offer the foremost POC systems on the market for quick, reliable diagnosis of acute events. Our launch product will be for the measurement of high sensitive troponin, to aid in the rule-in and rule-out of myocardial infarction.
The company’s share is traded on the NGM Nordic SME marketplace, under the ticker PRLD.
Attachments
Prolight Diagnostics - Investor letter August 1 2025
Prolight Diagnostics publishes investor letter for August 2025
Handelskrig
Apple
Analys
Handelskrig
Apple
Analys
1 DAG %
Senast
Handelskrig
1 augusti, 15:51
Professorn: "Svårt att tänka sig en guldålder"
Kempower
1 augusti, 12:28
Laddat för tillväxt i Kempower
Novo Nordisk
1 augusti, 10:47
1000 miljarder utraderade i Novo Nordisk
OMX Stockholm 30
1 DAG %
Senast
2 533,59